Interleukin-23 study in lupus and lung disease
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial looks at a protein called interleukin-23 in people with lupus, especially those who also have lung inflammation (interstitial lung disease). The goal is to understand more about this protein's role and possibly find new ways to help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with systemic lupus erythematosus (SLE, also known as lupus).
- You may or may not have a related lung condition called interstitial lung disease (ILD).
- You do not have other chest or lung problems besides ILD.
- You are not currently taking immune-blocking biologic therapies.
- You are not currently on immunosuppressive drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain substances in the blood, such as uric acid, homocysteine, and interleukin-17, are higher in people with lupus-related kidney disease compared to healthy individuals. It aims to find new ways to monitor or understand the condition better.
This study looks at whether a protein in the blood called interleukin-33 is linked to lupus symptoms)Skip
This study looks at how safe and effective a new type of medicine, called IL-23 inhibitors, is for people with ulcerative colitis or Crohn's disease. If you're starting this treatment for the first time, this study may help us learn more about how well it works.
This trial tests a new antibody drug (IL-23 inhibitor) for people with Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective. You may be able to join if you have moderate to severe disease and have not had certain bowel surgeries or infections.
This study looks at a type of white blood cell called eosinophils in people with interstitial lung disease (a group of conditions that cause lung scarring). It aims to understand if eosinophil levels are linked to the disease, which might help improve future treatments.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Hear when a new Systemic Lupus Erythematosus Related Interstial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.